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Letters to the Editor
Why Permanent Pacemaker
Implantation After Transcatheter
Aortic Valve Implantation
Does Not Affect Long-Term
Clinical Outcome
With interest, we took notice of the paper by Buellesfeld et al. (1)
investigating the impact of permanent pacemaker implantation on
clinical outcome after transcatheter aortic valve implantation
(TAVI) (1). The authors state that periprocedural permanent
pacemaker (PPM) implantation does not affect rate of death,
stroke, and/or myocardial infarction at 12 months compared with
patients with pre-existing PPM or patients without any PPM.
Because the findings of present study seem to contrast with
earlier observations from the MOST (Mode Selection Trial)
study and the DAVID (Dual Chamber and VVI Implantable
Defibrillator) trial, we have some concerns regarding the study
design (2,3).
First of all, Buellesfeld et al. (1) do not provide a power
calculation regarding the study size. Given the relatively low
number of patients, it is likely that the study is under-powered to
detect differences in the primary endpoint of all-cause mortality. It
is plausible than an endpoint combining all-cause mortality with
hospitalization for worsening of heart failure would have resulted
in different outcome between the groups. Indeed, the MOST and
DAVID trials, using similar endpoints, demonstrated that chronic
right ventricular pacing is associated with occurrence of heart
failure (2,3).Second, the PPM implantation strategy in the present study
eems rather liberal and early, with almost three-quarters of
mplantations occurring within 3 days after TAVI. As early
trioventricular conduction disorders post-TAVI are known to
ecover over time (4–6), a considerable number of patients would
ave received a PPM unnecessarily. Although scarce, there is some
vidence that during longer follow-up of TAVI-related PPM
mplantations, patients show no or limited pacemaker dependency
7) (unpublished data van der Boon RM, van Mieghem NM,
heuns DA, et al., 2012). Due to alterations in pacing mode, these
atients are not exposed to the unbeneficial effects of chronic right
entricle pacing.
We recently compared the impact of TAVI-induced left bundle
ranch block (LBBB) on all-cause mortality during long-term
ollow-up. In a cohort of 679 patients, all-cause mortality was
ignificantly higher among patients with TAVI-induced LBBB
ompared with patients without LBBB. Interestingly, the mortal-
ty rate among patients receiving PPM after TAVI was comparable
o that of patients without TAVI-induced LBBB. This discrep-
ncy could be explained by the low percentage of cumulative
entricular pacing in the PPM group (8).
In conclusion, in the present study by Buellesfeld et al. (1),
atient classification might be problematic as the post-TAVI PPM
atients are principally heterogeneous and are not all exposed to
he risks of (continuous) right ventricular pacing, which might
xplain the findings of the current study. We agree with the
uthors that larger-scaled studies are needed to further investigate
he impact of PPM after TAVI.
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Reply
We thank Dr. Houthuizen and colleagues for their interest in our
study (1), which reported that periprocedural permanent pace-
maker implantation among patients undergoing transcatheter aor-
tic valve implantation (TAVI) does not affect mortality during
follow-up through 1 year. Houthuizen and colleagues are con-
cerned by the lack of a sample size calculation and question the
validity of our findings in view of previous pacemaker studies,
namely, the MOST (Mode Selection Trial) and the DAVID
(Dual Chamber and VVI Implantable Defibrillator) trial (2,3), as
well as their own study suggesting a negative prognostic impact of
new onset left bundle branch block after TAVI (4).
Our study is the first report to address the impact of permanent
acemaker implantation on mortality among patients undergoing
AVI, and we acknowledge that our findings are exploratory and
ot conclusive as it was limited to 2 institutions and high-risk
atients. The number of patients and accumulated events were
mall, and 95% confidence intervals of hazard ratios wide. The
resent study should, therefore, be the impetus to address this issue
n prospectively planned larger cohort studies.
The MOST and the DAVID trials have shown a negative
mpact of right ventricular pacing by increasing heart failure
ospitalization but not mortality. Of note, these findings cannot be
xtrapolated to the issue of permanent pacemaker implantation in
he context of TAVI. Both the MOST study and the DAVID trial
ncluded only patients with sinus node dysfunction, in whom dual
hamber or right atrial pacing would have been technically suitable,
lternative pacing modes. Conversely, TAVI-related permanent
acemaker implantation is the result of transient or permanent
mpairment of atrioventricular (AV) conduction, which was an
xclusion criterion for participation in MOST and DAVID.
oreover, patients undergoing TAVI substantially differ from
atients included in the MOST and DAVID studies in terms of a
igher cardiac risk profile and comorbidities, rendering any extrap-
lation between these studies inappropriate.
As highlighted in the title of our manuscript, we analyzed the
ffect of pacemaker implantation rather than conduction distur-
ances on all-cause mortality. In view of rates of 1-year mortality
n the range of 24% to 31% after TAVI, it remains of interest
hether permanent pacemaker implantation as one of the most
requent TAVI adverse events has a prognostic impact on this
atient population.
As with any pacemaker population, the group of patients with
permanent pacemaker after TAVI is highly heterogeneous by
ature and consists of patients with various pacemaker indications(high-degree AV block, new-onset left bundle branch block with
first-degree AV block, slow atrial fibrillation), variable rates of
ventricular stimulation during follow-up, spontaneous recovery of
AV conduction no longer requiring a pacemaker, as well as
patients with recovery followed by relapse of severe conduction
abnormality. Therefore, the results of our study do not provide
insights on the clinical relevance of a specific conduction abnor-
mality, but describe the clinical prognosis of the event “TAVI-
related pacemaker implantation” under current practice standards.
These standards include post-procedural rhythm monitoring for
48 h to allow for AV conduction recovery and avoidance of
permanent pacemaker implantation in some patients, but also
includes early pacemaker implants in case of severe conduction
disturbances, as it effectively precludes deleterious effects related to
temporary pacemaker dislocation and bradycardia induced ventric-
ular fibrillation. In fact, a growing body of evidence indicates that
TAVI-induced conduction disturbances do not tend to recover
over time, supporting an early, aggressive strategy of permanent
pacemaker implantation (5).
The negative prognostic impact of left bundle branch block
among patients with cardiovascular disease, including ischemic
heart disease and dilated cardiomyopathy, has been previously
shown, and we read with interest the results of the study by
Houthuizen et al. among patients undergoing TAVI. Comparing
this study with ours, the results do not contradict but rather
complement each other as both studies address the issue of
TAVI-induced AV conduction abnormalities but from a different
angle. In this context, it is important to realize that patients
receiving a permanent pacemaker were specifically excluded from
the study by Houthuizen et al. (4), resulting in a different patient
population.
Pacemaker implantation is life-saving among patients with
high-degree AV conduction abnormalities, and it remains to be
seen whether some patients with TAVI-induced left bundle
branch block included in the study by Houthuizen et al. (4) would
have derived a benefit when implanted with a pacemaker. Given
the reports of both recovery as well as late onset of severe
conduction disturbances after TAVI, it remains a difficult clinical
judgment who should undergo permanent pacemaker implanta-
tion. Future efforts with focus both on how to avoid conduction
abnormalities and to define TAVI-specific criteria and on how to
treat them appropriately once they occur will importantly impact
the further evolution of TAVI.
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